Accordingly, CSF neurogranin has been proposed to be integrated as a potential new biomarker of synaptic degeneration and loss in the (N) group of the novel criteria for the diagnosis of AD, which was published by the National Institute on Aging and Alzheimer’s Association’s (NIA-AA) research framework [19]. Here, NRGN is linked to Alzheimer disease.